**Core Concept**
The CRASH-2 trial was a landmark study that investigated the effect of tranexamic acid (TXA) on mortality in patients with traumatic bleeding. The trial's findings have significant implications for the management of trauma patients, particularly those with severe bleeding.

**Why the Correct Answer is Right**
The CRASH-2 trial was a large, randomized controlled trial that included over 20,000 patients from 40 countries. The trial demonstrated that administration of tranexamic acid within 3 hours of injury significantly reduced the risk of death from bleeding. This effect was observed in patients with both penetrating and blunt trauma. Tranexamic acid works by inhibiting fibrinolysis, thereby stabilizing clots and preventing excessive bleeding.

**Why Each Wrong Option is Incorrect**
**Option A:** This statement is true. The CRASH-2 trial did indeed show that tranexamic acid reduced the risk of death from bleeding in trauma patients.
**Option B:** This statement is also true. The trial found that the beneficial effect of tranexamic acid was most pronounced when administered within 3 hours of injury.
**Option C:** This statement is true as well. The CRASH-2 trial demonstrated a significant reduction in the risk of death from bleeding in patients with traumatic injury, regardless of the cause of the bleeding.

**Clinical Pearl / High-Yield Fact**
A key takeaway from the CRASH-2 trial is that tranexamic acid should be administered promptly in patients with suspected traumatic bleeding, ideally within 3 hours of injury. This can significantly improve outcomes and reduce mortality in these patients.

**Correct Answer: None of the above.**

✓ Correct Answer: D. Tranexamic acid reduces the risk of moality from bleeding in blunt trauma but not in penetrating trauma